Canada markets open in 7 hours 5 minutes

Pacific Biosciences of California, Inc. (PACB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
23.21+0.15 (+0.65%)
At close: 04:00PM EST
22.69 -0.52 (-2.24%)
After hours: 07:56PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close23.06
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range22.62 - 23.85
52 Week Range16.70 - 53.69
Avg. Volume1,893,077
Market Cap5.12B
Beta (5Y Monthly)1.10
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    PacBio Names Jason Kang as Vice President and General Manager for Asia-Pacific Region

    Strategic hire will expand Company’s commercial presence in key geographyMENLO PARK, Calif., Nov. 30, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, long-read sequencing platforms, welcomes Jason Kang as Vice President and General Manager for the company’s Asia-Pacific region. Jason will be responsible for leading and developing PacBio’s commercial team in Asia-Pacific as the company continues to expand its reach in the region to support rapidly growing demand

  • GlobeNewswire

    Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

    CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company’s Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Co

  • GlobeNewswire

    PacBio Grants Equity Incentive Award to New Employee

    MENLO PARK, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 80,000 shares of PacBio common stock, and restricted stock units (“RSUs”) covering 40,000 shares of PacBio common stock, to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity I